Search Results | Cancer Research | American Association for Cancer Research

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Abstract 5848: Inhibition of the CRM1 nuclear export protein can treat mutant KRAS tumors through stabilizing the DLC1 tumor suppressor protein

Brajendra K. Tripathi, Nicole Hirsh, Xiaolan Qian, Dunrui Wang, Marian E. Durkin, Fernando J. de Miguel, Katerina Politi, James H. Doroshow, Douglas R. Lowy

Cancer Res (2022) 82 (12_Supplement): 5848.

DOI: https://doi.org/10.1158/1538-7445.AM2022-5848

Published: 15 June 2022

View article

Journal Articles

Abstract 3912: cProSite: A web based interactive platform for on-line proteomics and phosphoproteomics data analysis

Dunrui Wang, Xiaolan Qian, Yi-Chieh Nancy Du, Beatriz Sanchez-Solana, Kailing Chen, Brian Park, Ben Chen, Lisa Jenkins, Jason Luo, Brajendra K. Tripathi, Marian E. Durkin, Douglas R. Lowy

Cancer Res (2022) 82 (12_Supplement): 3912.

DOI: https://doi.org/10.1158/1538-7445.AM2022-3912

Published: 15 June 2022

View article

Journal Articles

Abstract 2508: Targeting mutant KRAS tumors by inhibiting cytoplasmic EZH2, which directly methylates and destabilizes the DLC1 tumor suppressor protein

Brajendra K. Tripathi, Disha Bhargava, Xiaolan Qian, Dunrui Wang, Marian E. Durkin, Fernando J. de Miguel, Katerina Politi, Kylie J. Walters, James H. Doroshow, Douglas R. Lowy

Cancer Res (2021) 81 (13_Supplement): 2508.

DOI: https://doi.org/10.1158/1538-7445.AM2021-2508

Published: 01 July 2021

View article

Journal Articles

Cancer-Associated Point Mutations in the DLC1 Tumor Suppressor and Other Rho-GAPs Occur Frequently and Are Associated with Decreased Function

Dunrui Wang, Xiaolan Qian, Beatriz Sanchez-Solana, Brajendra K. Tripathi, Marian E. Durkin, Douglas R. Lowy

Cancer Res (2020) 80 (17): 3568–3579.

DOI: https://doi.org/10.1158/0008-5472.CAN-19-3984

Published: 02 September 2020

View article

Includes: Supplementary data

Journal Articles

Abstract 3431: Epigenetic reactivation of the DLC1 tumor suppressor protein is a new approach for cancer treatment

Brajendra K. Tripathi, Luciarita Boccuzzi, Meghan Anderman, Xiaolan Qian, Kylie J. Walters, James H. Doroshow, Douglas R. Lowy

Cancer Res (2020) 80 (16_Supplement): 3431.

DOI: https://doi.org/10.1158/1538-7445.AM2020-3431

Published: 15 August 2020

View article

Journal Articles

Abstract 4513: Targeting the DLC1 Rho-GAP tumor suppressor protein to treat solid tumors

Brajendra K. Tripathi, Meghan F. Anderman, James H. Doroshow, Douglas R. Lowy

Cancer Res (2019) 79 (13_Supplement): 4513.

DOI: https://doi.org/10.1158/1538-7445.AM2019-4513

Published: 01 July 2019

View article

Journal Articles

Abstract 3957: SRC inhibitors dephosphorylate and reactivate the DLC1 tumor suppressor: A new biomarker of clinical response

Brajendra K. Tripathi, Meghan Anderman, Xiaolan Qian, Ming Zhou, Dunrui Wang, Alex G. Papageorge, Douglas R. Lowy

Cancer Res (2018) 78 (13_Supplement): 3957.

DOI: https://doi.org/10.1158/1538-7445.AM2018-3957

Published: 01 July 2018

View article

Journal Articles

Abstract 1364: Direct phosphorylation and attenuation of the DLC1 tumor suppressor by SRC kinase: a new mechanism of SRC-dependent activation of Rho with translational implications

Brajendra K. Tripathi, Xiaolan Qian, Ming Zhou, Dunrui Wang, Marian Durkin, Alex G. Papageorge, Douglas R. Lowy

Cancer Res (2017) 77 (13_Supplement): 1364.

DOI: https://doi.org/10.1158/1538-7445.AM2017-1364

Published: 01 July 2017

View article

Journal Articles

Abstract 4377: AKT positively regulates Rho-GTP by attenuating the GAP activity of the DLC1 tumor suppressor: a mechanistic study with translational implications

Brajendra K. Tripathi, Tiera Grant, Philipp Mertins, Xiaolan Qian, Dunrui Wang, Alex G. Papageorge, Steven A. Carr, Douglas R. Lowy

Cancer Res (2016) 76 (14_Supplement): 4377.

DOI: https://doi.org/10.1158/1538-7445.AM2016-4377

Published: 15 July 2016

View article

Journal Articles

Abstract 888: Inactivation of the DLC1 RhoGAP tumor suppressor by point mutation occurs commonly in human cancer and can result from Rho-dependent or Rho-independent mechanisms

Xiaolan Qian, Dunrui Wang, Beatriz Sanchez-Solana, Brajendra K. Tripathi, Marian E. Durkin, Alex Papageorge, Douglas R. Lowy

Cancer Res (2016) 76 (14_Supplement): 888.

DOI: https://doi.org/10.1158/1538-7445.AM2016-888

Published: 15 July 2016

View article

Journal Articles

Abstract 2155: Inactivation of the tumor suppressor DLC1 by the oncogenes SRC and ERK1 in lung adenocarcinoma

Brajendra K. Tripathi, Xiaolan Qian, Tiera Grant, Philipp Mertins, Dunrui Wang, Alex G. Papageorge, Steven A. Carr, Douglas R. Lowy

Cancer Res (2015) 75 (15_Supplement): 2155.

DOI: https://doi.org/10.1158/1538-7445.AM2015-2155

Published: 01 August 2015

View article

Journal Articles

Abstract 1574: CDK5 negatively regulates Rho by phosphorylating and activating the Rho-GAP and tumor suppressor functions of DLC1

Brajendra K. Tripathi, Xiaolan Qian, Philipp Mertins, Dunrui Wang, Alex Papageorge, Steven Carr, Douglas R. Lowy

Cancer Res (2014) 74 (19_Supplement): 1574.

DOI: https://doi.org/10.1158/1538-7445.AM2014-1574

Published: 01 October 2014

View article

Journal Articles

Inactivation of the Dlc1 Gene Cooperates with Downregulation of p15^INK4b and p16^Ink4a, Leading to Neoplastic Transformation and Poor Prognosis in Human Cancer

Xiaolan Qian, Marian E. Durkin, Dunrui Wang, Brajendra K. Tripathi, Lyra Olson, Xu-Yu Yang, William C. Vass, Nicholas C. Popescu, Douglas R. Lowy

Cancer Res (2012) 72 (22): 5900–5911.

DOI: https://doi.org/10.1158/0008-5472.CAN-12-2368

Published: 14 November 2012

View article

Includes: Supplementary data

Journal Articles

Abstract 1436: The Cdk5 activator p39 specifically links muskelin to myosin and regulates stress fiber organization and contraction

Brajendra K. Tripathi, Douglas R. Lowy, Peggy S. Zelenka

Cancer Res (2011) 71 (8_Supplement): 1436.

DOI: https://doi.org/10.1158/1538-7445.AM2011-1436

Published: 15 April 2011

View article

NARROW

Abstract 5848: Inhibition of the CRM1 nuclear export protein can treat mutant KRAS tumors through stabilizing the DLC1 tumor suppressor protein

Abstract 3912: cProSite: A web based interactive platform for on-line proteomics and phosphoproteomics data analysis

Abstract 2508: Targeting mutant KRAS tumors by inhibiting cytoplasmic EZH2, which directly methylates and destabilizes the DLC1 tumor suppressor protein

Cancer-Associated Point Mutations in the DLC1 Tumor Suppressor and Other Rho-GAPs Occur Frequently and Are Associated with Decreased Function

Abstract 3431: Epigenetic reactivation of the DLC1 tumor suppressor protein is a new approach for cancer treatment

Abstract 4513: Targeting the DLC1 Rho-GAP tumor suppressor protein to treat solid tumors

Abstract 3957: SRC inhibitors dephosphorylate and reactivate the DLC1 tumor suppressor: A new biomarker of clinical response

Abstract 1364: Direct phosphorylation and attenuation of the DLC1 tumor suppressor by SRC kinase: a new mechanism of SRC-dependent activation of Rho with translational implications

Abstract 4377: AKT positively regulates Rho-GTP by attenuating the GAP activity of the DLC1 tumor suppressor: a mechanistic study with translational implications

Abstract 888: Inactivation of the DLC1 RhoGAP tumor suppressor by point mutation occurs commonly in human cancer and can result from Rho-dependent or Rho-independent mechanisms

Abstract 2155: Inactivation of the tumor suppressor DLC1 by the oncogenes SRC and ERK1 in lung adenocarcinoma

Abstract 1574: CDK5 negatively regulates Rho by phosphorylating and activating the Rho-GAP and tumor suppressor functions of DLC1

Inactivation of the Dlc1 Gene Cooperates with Downregulation of p15^INK4b and p16^Ink4a, Leading to Neoplastic Transformation and Poor Prognosis in Human Cancer

Abstract 1436: The Cdk5 activator p39 specifically links muskelin to myosin and regulates stress fiber organization and contraction

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only